Mirum Pharmaceuticals, Inc. MIRM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$790.16M-5,284% | -$5.73M+75.9% | $2.91M+120% | -$5.86M+76.2% | -$14.68M+41.9% | ||
| $6.87M+13.6% | $6.07M+0.3% | $6.06M+0.1% | $6.06M+3.5% | $6.05M+6.9% | ||
| $36.2M+129% | $19.03M+43.6% | $18.13M+52.2% | $18.47M+56.0% | $15.8M+38.0% | ||
| $454K+4.8% | $436K+4.8% | $443K+4.5% | $427K+4.9% | $433K+4.6% | ||
| $12.89M-23.4% | $19.01M+75.0% | $3.15M-61.2% | $9.07M+67.0% | $16.83M+230% | ||
| $1.92M-28.1% | $2.28M+966% | $1.16M+28.3% | $2.34M+115% | $2.67M+177% | ||
| $6.63M+119% | —— | $4.63M+33.6% | $4.09M+386% | $3.03M+430% | ||
| $278K-21.9% | $382K+3.2% | $345K-23.3% | $318K+24.2% | $356K+227% | ||
| -$583K-42.9% | -$513K-140% | -$580K-447% | -$395K-105% | -$408K-51.7% | ||
| -$228.76M-11,566% | $6.07M— | $39.68M+896% | $12.04M— | -$1.96M-113% | ||
| $664K+1,520% | $600K+2,900% | $187K+3.3% | $126K-83.8% | $41K+215% | ||
| $34.8M+3.8% | $11.5M+0.2% | $20.86M+33.7% | $31.54M-49.1% | $33.53M— | ||
| $33.89M+94.4% | $13.11M+7.9% | $18.82M+143% | $25.06M— | $17.43M— | ||
| $10M— | $0— | $0-100% | $0-100% | $0— | ||
| -$11.57M+28.3% | $0— | -$2.23M+87.7% | -$6.6M+90.9% | -$16.13M-124,008% | ||
| $10.13M+59.3% | -$31.14M— | $16.1M— | $8.69M— | $6.36M— | ||
| $270.08M+4,147% | $9M+68.5% | $16.1M+317% | $8.69M+19.2% | $6.36M+428% | ||
| -$1.27M-221% | —— | $349K+297% | $2.23M+1,971% | $1.06M+834% | ||
| $28.48M+367% | $15.66M+3,461% | $53.9M+634% | $16.36M+124% | -$10.68M-165% | ||
| $220K+35.8% | $6K-97.4% | $504K+16.7% | $1.49M+643% | $162K+16.5% | ||
| $454K+4.8% | $436K+4.8% | $443K+4.5% | $427K+4.9% | $433K+4.6% | ||
| $998K— | —— | —— | —— | $0— | ||
| $415.27M— | —— | —— | —— | $0— | ||
| -$1.1M-267% | —— | $643K+164% | $612K+53.0% | $658K-62.1% | ||
| $57.24M+388% | $3.44M-63.1% | $24.35M+90.9% | $10.58M+52.3% | $11.74M+4.1% | ||
| $71.79M— | —— | —— | —— | $0— | ||
| -$583K-42.9% | -$513K-140% | -$580K-447% | -$395K-105% | -$408K-51.7% | ||
| $4.8M+5,113% | $1.64M+81,750% | $2.68M+90.6% | $1.25M+1,163% | $92K+936% | ||
| $6.63M+119% | —— | $4.63M+33.6% | $4.09M+386% | $3.03M+430% | ||
| $0+100% | —— | -$540K-405% | —— | -$2.35M-891% | ||
| $550K+41.0% | $457K+23.8% | $447K+11.8% | $436K+25.3% | $390K+64.6% | ||
| $278K-21.9% | $382K+3.2% | $345K-23.3% | $318K+24.2% | $356K+227% | ||
| $10M— | $0— | $0-100% | $0-100% | $0— | ||
| $33.89M+94.4% | $13.11M+7.9% | $18.82M+143% | $25.06M— | $17.43M— | ||
| $259.95M— | —— | —— | —— | $0— | ||
| $10.13M+59.3% | $9M+68.5% | $16.1M+317% | $8.69M+19.2% | $6.36M+428% | ||
| $0-100% | $7K— | $8K— | $3K— | $6K— | ||
| -$1.27M-221% | —— | $349K+297% | $2.23M+1,971% | $1.06M+834% | ||
| -$583K-42.9% | -$513K-140% | -$580K-447% | -$395K-105% | -$408K-51.7% | ||
| $810K+38.9% | $686K+74.6% | $757K+171% | $564K+80.2% | $583K+102% | ||
| $0-100% | —— | —— | —— | $649K-10.2% | ||
| $4.47M— | $771K— | $0-100% | $1.67M— | $0— | ||
| $173K-18.4% | $145K-31.9% | $241K+12.1% | $90K-81.3% | $212K-0.9% | ||
| $9.56M— | —— | —— | —— | $0— | ||
| $220K+35.8% | $6K-97.4% | $504K+16.7% | $1.49M+643% | $162K+16.5% | ||
| -$229.43M-11,360% | $5.47M— | $39.49M+938% | $11.91M— | -$2M-113% | ||
| -$229.43M-11,360% | $5.47M— | $39.49M+938% | $11.91M— | -$2M-113% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Mirum Pharmaceuticals, Inc. generate?
- Mirum Pharmaceuticals, Inc. (MIRM) generated -$171.0M in operating cash flow over the trailing twelve months.
- What is Mirum Pharmaceuticals, Inc.'s free cash flow?
- After $1.6M of capital expenditures, Mirum Pharmaceuticals, Inc.'s free cash flow was -$172.6M over the trailing twelve months, down 45270.7% year over year.
- Where does Mirum Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
